Little-known drugs are now contributing to the US overdose epidemic; the Government Accountability Office finds HHS is at "High Risk Alert"; Moderna begins HIV vaccine trial.
Two little-known drugs, para-fluorofentanyl and metonitazene, are contributing to the nation’s overdose crisis, as they are being seen more often by medical examiners looking into the deaths, a new government report found. According to The Associated Press, these drugs are usually taken with or mixed in with fentanyl, one of the main contributors of the over 100,000 overdose deaths reported in the United States in 2021. However, the drugs are also more powerful than fentanyl and are increasingly the sole reason for some deaths. Naloxone can still work in cases where the 2 drugs are ingested, but more may be needed per case.
A new Government Accountability Office (GAO) report found HHS has failed to fix problems in its pandemic response, threatening the agency’s efficacy in responding to future crises, Politico reports. HHS is now on what the GAO deems “High Risk Alert,” meaning it is susceptible to mismanagement and abuse in the absence of significant changes. An additional 3 dozen agencies are also deemed at high risk. Among the failures outlined are leadership shortcomings, difficulties in collecting and analyzing data, and problems communicating with the public. In Congress, members are calling for the implementation of new guardrails for future emergencies handled by HHS.
Moderna has initiated its trial of an HIV vaccine that uses mRNA technology, ABC News reports. The first participants received doses of the vaccine on January 27, and the trial is in partnership with the International AIDS Vaccine Initiative. Approximately 38 million individuals around the world are currently living with HIV, including 1.3 million in the United States. Throughout the height of the US AIDS epidemic, around 50,000 deaths occurred each year while today, advances in treatment allow patients to manage the virus to the point where viral loads can become undetectable, preventing transmission.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More